Completed PHASE4 INTERVENTIONAL 2-arm NCT04619303

Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO (OASIS)

A Randomized Clinical Trial of Intravitreal dexamethasOne Versus Bevacizumab in Aboriginal and Torres Strait Islander patientS With Diabetic Macular Oedema (The OASIS Study)

Sponsor: Allergan

Conditions Diabetic Macular Edema Diabetic Retinopathy

Interventions Bevacizumab Injectable Product Dexamethasone intravitreal implant

Updated 5 times since 2020 Last updated: Nov 5, 2020 Started: Feb 7, 2017 Primary completion: Feb 14, 2020 Completion: Feb 14, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04619303, this PHASE4 trial focuses on Diabetic Macular Edema and Diabetic Retinopathy and remains completed. Sponsored by Allergan, it has been updated 5 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Dec 2020 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Feb 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan
Lions Eye Institute, Perth, Western Australia
Lions Outback Vision

Data source: Lions Eye Institute, Perth, Western Australia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Broome, Australia , Derby, Australia , Fitzroy Crossing, Australia , Halls Creek, Australia , Kalgoorlie-Boulder, Australia , Karratha, Australia , Kununurra, Australia , Laverton, Australia , Perth, Australia , Roebourne, Australia and 1 more location